Multiple psoriasis-related molecular targets

Multiple psoriasis-related molecular targets refers to a non-specific grouping of biological entities and pathways involved in the pathogenesis of psoriasis, rather than a single discrete protein. Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by the hyperproliferation of keratinocytes and significant immune cell infiltration, primarily driven by the IL-23/IL-17 cytokine axis and Tumor Necrosis Factor-alpha (TNF-alpha) (Source: StatPearls, PMID: 29939612). Because the disease involves a complex network of interacting cytokines, chemokines, and intracellular signaling molecules like Janus kinases (JAK) and phosphodiesterase-4 (PDE4), many therapeutic interventions aim to modulate several of these components simultaneously (Source: Nature Reviews Disease Primers, PMID: 27905471). This designation is often used in pharmacological databases to categorize compounds that exhibit polypharmacology or for which a single, primary validated target has not been definitively isolated despite demonstrated clinical efficacy. Consequently, drugs associated with this category may act on a variety of receptors and enzymes to reduce cutaneous inflammation and normalize skin cell turnover (Source: Journal of Investigative Dermatology, PMID: 31521659).

Other names

Psoriasis-associated molecular targetsNon-specific psoriasis targetsPsoriasis-related inflammatory mediators

Broad-spectrum modulation of inflammatory cytokine production, inhibition of T-cell activation, and suppression of keratinocyte hyperproliferation through multiple signaling pathways including the IL-23/IL-17 axis and TNF-alpha signaling.